Ms. Smith was introduced to Nivalis Therapeutics through LifeSci Advisors's Board Placement Initiative (BPI), a program started earlier this year to help life sciences companies diversify their corporate boards. "LifeSci's Board Placement initiative expanded Nivalis' network of highly qualified candidates with the specific expertise we sought to add to our Board" said Jon Congleton. Ms. Smith is also one of the 20 executives who recently completed the Women In Bio's Boardroom Ready Program.About Nivalis Therapeutics, Inc.Nivalis Therapeutics, Inc. ( http://www.nivalis.com) is a clinical-stage pharmaceutical company committed to the discovery, development and commercialization of therapeutics for people with CF. In addition to developing innovative solutions intended to extend and improve the lives of people with CF, Nivalis plans to utilize its proprietary GSNOR inhibitor portfolio to develop therapeutics for other diseases. About CavosonstatCavosonstat works through a novel mechanism of action called GSNOR inhibition that is presumed to modulate the unstable and defective CFTR protein responsible for CF. GSNOR inhibition restores GSNO levels thereby modifying the chaperones responsible for CFTR protein degradation. This stabilizing effect has been shown to increase and prolong the function of the CFTR chloride channel and increase net chloride secretion in preclinical experiments. Nivalis discovered and owns exclusive rights to cavosonstat in the United States (U.S.) and all other major markets, including U.S. composition of matter patent protection until at least 2031. Cavosonstat was granted Orphan Drug and Fast Track designations by the FDA earlier this year. Nivalis Therapeutics has completed clinical studies with cavosonstat, including a Phase 1a dose-escalation safety study in healthy volunteers, and a Phase 1b safety study in people with CF who have two copies of the F508del-CFTR mutation. In preclinical studies, cavosonstat has been shown to increase the function of F508del-CFTR, the mutant protein that is estimated to be present in approximately 86 percent of people with CF in the United States and Europe. About Cystic FibrosisCF is a life-shortening genetic disease that affects an estimated 70,000 people worldwide, predominantly in the United States and Europe, according to the Cystic Fibrosis Foundation ( www.cff.org). CF is characterized by a defect in the chloride channel known as the "cystic fibrosis transmembrane conductance regulator," or CFTR, and is caused by mutations in the CFTR gene.
Contacts:Investor Relations John Graziano1firstname.lastname@example.orgMedia Relations Lindsay Rocco1email@example.com